Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: Correlation with cancer antigen 125 and tumor-associated trypsin inhibitor

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 7, 1997, Pages 2308-2313

  Flyvbjerg, Allan ^a   Mogensen, Ole ^a   Mogensen, Bent ^a   Nielsen, Ole Steen ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; CA 125 ANTIGEN; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER DIAGNOSIS; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FEMALE; HUMAN; OVARY CANCER; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CA-125 ANTIGEN; ENDOPEPTIDASES; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RADIOIMMUNOASSAY; TRYPSIN INHIBITORS;

EID: 0030752414     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.82.7.2308     Document Type: Article

References (25)

1. Shimasaki S, Shimonaka M, Zhang H-P, Ling N. 1991 Identification of five different IGFBPs from adult rat serum and molecular cloning of a novel IGFBP-5 in rat and human. J Biol Chem. 266:10646-10653.
2. Shimasaki S, Gao L, Shimonaka M, Ling N. 1991 Isolation and molecular cloning of IGFBP-6. Mol Endocrinol. 5:938-948.
3. Giudice LC. 1992 Insulin-like growth factors and ovarian follicular development. Endocr Rev. 13:641-669.
4. Adashi EY. 1994 Regulation of intrafollicular IGFBPs: possible relevance to ovarian follicular selection. In: Baxter RC, Gluckman PD, Rosenfeld RG, eds. The insulin-like growth factors and their regulatory proteins. Amsterdam: Elsevier Science B.V.; 341-349.
5. Karasik A, Menczer Y, Pariente C, Kanety H. 1994 Insulin-like growth factor I (IGF-I) and IGF-binding protein 2 are increased in cyst fluids of epithelial ovarian cancer. J Clin Endocrinol Metab. 78:271-276.
6. Kanety H, Kattan M, Goldberg I, et al. 1996 Increased insulin-like growth factor binding protein 2 (IGFBP-2) gene expression and protein production lead to high IGFBP-2 content in malignant ovarian cyst fluid. Br J Cancer. 73:1069-1073.
7. Bast Jr RC, Klug TL, John ES, et al. 1983 A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 309:883-887.
8. Mogensen O, Mogensen B, Jacobsen A. 1989 CA 125 in the diagnosis of pelvic masses. Eur J Cancer Clin Oncol. 25:1187-1190.
9. Mogensen O, Mogensen B, Jacobsen A. 1990 Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours. Br J Cancer. 61:327-329.
10. Mogensen O, Mogensen B, Jacobsen A. 1990 Tumour-associated trypsin inhibitor and cancer antigen 125 in pelvic masses. Gynecol Oncol. 38:170-174.
11. Hossenlopp P, Seurin D, Segovia-Quinson B, Hardouin S, Binoux M. 1986 Analysis of serum insulin-like growth factor binding proteins using Western blotting: use of the method for titration of the binding proteins and competitive binding studies. Anal Biochem. 154:138-143.
12. Flyvbjerg A, Kessler U, Dorka B, et al. 1992 Transient increase in renal insulin-like growth factor binding proteins during initial kidney hypertrophy in experimental diabetes in rats. Diabetologia. 35:589-593.
13. Lamson G, Giudice LC, Rosenfeld RG. 1991 A simple assay for proteolysis of ICFBP-3. J Clin Endocrinol Metab. 72:1391-1393.
14. Yee D, Morales FR, Hamilton TC, von Hoff DD. 1991 Expression of insulin-like growth factor I, its binding proteins, and its receptor in ovarian cancer. Cancer Res. 51:5107-5112.
15. Huhtala ML, Pesonen K, Kalkkinen N, Stenman UH. 1982 Purification and characterization of a tumor-associated trypsin inhibitor from the urine of patients with ovarian cancer. J Biol Chem. 257:13713-13716.
16. Huhtala ML. 1984 Demonstration of a new acrosin inhibitor in human seminal plasma. Hoppe-Seyler's Z. Physiol Chem. 365:819-825.
17. Stenman UH, Koivunen E, Itkonen O. 1991 Biology and function of tumor-associated trypsin inhibitor. Scand J Clin Lab Invest. [Suppl 207]51:5-9.
18. Hossenlopp P, Sergovia-Quinson B, Lassarre C, et al. 1990 Evidence of enzymatic degradation of insulin-like growth factor binding proteins in the 150K complex during pregnancy. J Clin Endocrinol Metab. 71:797-805.
19. Davenport MS, Isley WI, Pucilowska JB, et al. 1992 Insulin-like growth factor binding protein 3 proteolysis is induced after elective surgery. J Clin Endocrinol Metab. 75:590-595.
20. Davies SC, Wass JA, Ross RJ, et al. 1991 The induction of a specific protease for insulin-like growth factor binding protein 3 in the circulation during severe illness. J Endocrinol. 130:469-473.
21. Bang P, Brismar K, Rosenfeld RG. 1994 Increased proteolysis of insulin-like growth factor binding protein 3 (IGFBP-3) in noninsulin-dependent diabetes mellitus serum, with elevation of a 29-kilodalton (kDa) glycosylated IGFBP-3 fragment contained in the approximately 130- to 150-kDa ternary complex. J Clin Endocrinol Metab. 78:1119-1127.
22. Bang P. 1995 Serum proteolysis of IGFBP-3. Prog Growth Factor Res. 6:285-292.
23. Cohen P, Peehl DM, Lamson G, Rosenfeld RG. 1991 Insulin-like growth factors (IGFs), IGF receptors and IGF binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab. 73:401-407.
24. Cohen P, Peehl DM, Stamey TA, et al. 1993 Elevated levels of insulin-like growth factor binding protein 2 in the serum of prostate cancer patients. J Clin Endocrinol Metab. 76:1031-1035.
25. Kanety H, Madjar Y, Dagan Y, et al. 1993 Serum insulin-like growth factor binding protein 2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab. 77:229-233.